ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor

Abstract

Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug resistance. In a previous study, we identified a gene signature, consisting mainly of Kruppel-associated box (KRAB) domain containing zinc finger (ZNF) transcriptional repressors that predict short-term… (More)
DOI: 10.1371/journal.pone.0054477

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Rink2013ZNFMediatedRT, title={ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor}, author={Lori Rink and Michael F. Ochs and Yan Zhou and Margaret M von Mehren and Andrew K. Godwin}, booktitle={PloS one}, year={2013} }